Abstract
Sickle cell disease (SCD) is a potentially devastating and life threatening condition that is caused by an autosomal recessive inherited hemoglobinopathy which results in vaso-occlusive phenomena and hemolysis. The severity of this disorder is widely variable, but overall mortality is increased and life expectancy decreased when compared to the general population.
Care of patients with sickle cell disease is largely supportive. In fact, hydroxyurea is the only drug used that modifies disease pathogenesis. Painful vaso-occlusive events are the most common complication experienced by both children and adults with sickle cell disease and hydroxyurea is the only treatment option available to prevent the development of these events. Most events are managed with traditional supportive care measures (i.e. aggressive hydration, antiinflammatory and narcotic analgesics) that have not changed in decades. As such, there is an overwhelming need for both the development of new agents and new approaches to treatment with existing modalities for patients with sickle cell disease.
Keywords: Sickle cell disease, therapeutics, treatment, children.
Current Pharmaceutical Design
Title:Pharmacotherapy of Sickle Cell Disease in Children
Volume: 21 Issue: 39
Author(s): Kathleen A. Neville and Julie A. Panepinto
Affiliation:
Keywords: Sickle cell disease, therapeutics, treatment, children.
Abstract: Sickle cell disease (SCD) is a potentially devastating and life threatening condition that is caused by an autosomal recessive inherited hemoglobinopathy which results in vaso-occlusive phenomena and hemolysis. The severity of this disorder is widely variable, but overall mortality is increased and life expectancy decreased when compared to the general population.
Care of patients with sickle cell disease is largely supportive. In fact, hydroxyurea is the only drug used that modifies disease pathogenesis. Painful vaso-occlusive events are the most common complication experienced by both children and adults with sickle cell disease and hydroxyurea is the only treatment option available to prevent the development of these events. Most events are managed with traditional supportive care measures (i.e. aggressive hydration, antiinflammatory and narcotic analgesics) that have not changed in decades. As such, there is an overwhelming need for both the development of new agents and new approaches to treatment with existing modalities for patients with sickle cell disease.
Export Options
About this article
Cite this article as:
A. Neville Kathleen and A. Panepinto Julie, Pharmacotherapy of Sickle Cell Disease in Children, Current Pharmaceutical Design 2015; 21 (39) . https://dx.doi.org/10.2174/1381612821666151030105213
DOI https://dx.doi.org/10.2174/1381612821666151030105213 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutrigenetics, Metabolic Syndrome Risk and Personalized Nutrition
Current Vascular Pharmacology Left Ventricular Hypertrophy in Isolated Aortic Stenosis: Primetime for the Ventricle
Current Pharmaceutical Biotechnology Limiting Functional Deficiency Following Stroke: Exploiting Different Stem Cell Reservoirs
Current Neuropharmacology Micronutrient Biofortification in Rice through New Breeding Techniques (NBTs): Bangladesh Perspective
Current Nutraceuticals Host Defence Cryptides from Human Apolipoproteins: Applications in Medicinal Chemistry
Current Topics in Medicinal Chemistry Chemokines in Cardiovascular Remodeling: Clinical and Therapeutic Implications
Current Molecular Medicine Recent Advances in Nanoparticle Carriers for Coordination Complexes
Current Topics in Medicinal Chemistry Statins and Cardiovascular Diseases: From Cholesterol Lowering to Pleiotropy
Current Pharmaceutical Design Eplerenone, a New Selective Aldosterone Blocker
Current Pharmaceutical Design Possible Underestimation by Sports Medicine of the Effects of Early Physical Exercise Practice on the Prevention of Diseases in Adulthood
Current Diabetes Reviews The Updated Role of the Blood Brain Barrier in Subarachnoid Hemorrhage: From Basic and Clinical Studies
Current Neuropharmacology Hypertension and Atrial Fibrillation: Any Change with the New Anticoagulants
Current Pharmaceutical Design Hyperhomocysteinemia in L-Dopa Treated Patients with Parkinsons Disease: Potential Implications in Cognitive Dysfunction and Dementia?
Current Medicinal Chemistry Chalcones as Versatile Synthons for the Synthesis of 5- and 6-membered Nitrogen Heterocycles
Current Organic Chemistry Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets Intravenous Thrombolysis with rt-PA in Acute Stroke Patients Aged ≥80 Years
Letters in Drug Design & Discovery Bioenergetics and Mitochondrial Dysfunction in Aging: Recent Insights for a Therapeutical Approach
Current Pharmaceutical Design The Influence of Microneedles on the Percutaneous Penetration of Selected Antihypertensive Agents: Diltiazem Hydrochloride and Perindopril Erbumine
Current Drug Delivery Controversial Issues of Abortion License According to Religious and Jurisprudential Laws in Iran: A Systematic Review
Current Women`s Health Reviews Therapeutic Targets for Management of Periodontitis and Diabetes
Current Pharmaceutical Design